Evidence map›Paper›PMID 35072118›Full record

ArticleEuropean urology open science2022

Online Public Interest in Urological Cancers During the COVID-19 Pandemic: What Can "Dr. Google" Teach Us?

Zine-Eddine Khene, Sonia Guérin, Fares Khene, Benjamin Pradère, Mathieu Roumiguié, Romain Mathieu, Géraldine Pignot, Christophe Massard, Yann Neuzillet, Guillaume Ploussard and 5 more

Open access · goldAbstract read
In one paragraph

Article in European urology open science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Trends in public interest and vaccination coverage for Herpes Zoster.Public health in practice (Oxford, England) · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 2 countries.

Zine-Eddine KheneDepartment of Urology, Rennes University Hospital, Rennes, France.
Sonia GuérinDepartment of Urology, Rennes University Hospital, Rennes, France.
Fares KheneDepartment of Urology, Rennes University Hospital, Rennes, France.
Benjamin PradèreDepartment of Urology, Medical University Vienna, General Hospital, Vienna, Austria.
Mathieu RoumiguiéDepartment of Urology, University of Toulouse, Toulouse, France.
Romain MathieuDepartment of Urology, Rennes University Hospital, Rennes, France.
Géraldine PignotDepartment of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France.
Christophe MassardDepartment of Medical Oncology, Centre Eugène Marquis, Rennes, France.
Yann NeuzilletDepartment of Urology, Foch Hospital, University of Versailles-Saint-Quentin-en-Yvelines, Suresnes, France.
Guillaume PloussardLa Croix du Sud Hospital, Quint Fonsegrives, France.
Pierre BigotDepartment of Urology, University of Angers, Angers, France.
Alexandre De la TailleDepartment of Urology, Mondor Hospital, Créteil, France.
Morgan RouprêtUrology, GRC 5 Predictive Onco-Uro, AP-HP, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France.
Karim BensalahDepartment of Urology, Rennes University Hospital, Rennes, France.
Members of the French Committee of Urologic Oncology CCAFU
Centre Hospitalier Universitaire de Rennes · FRCentre Eugène Marquis · FRInstitut Mondor de Recherche Biomédicale · FRInstitut Paoli-Calmettes · FRInstitut universitaire du cancer de Toulouse Oncopole · FRPitié-Salpêtrière Hospital · FRUniversité d'Angers · FRUniversité de Toulouse · FRUniversité de Versailles Saint-Quentin-en-Yvelines · FRVienna General Hospital · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe coronavirus disease 2019 (COVID-19) pandemic has greatly affected health care priorities.

objectiveTo explore and analyse trends in public online search for urological cancers. DESIGN SETTING AND

participantsWe performed a retrospective analysis using the Google Health Trends online tool. Data related to urological cancer terms ("prostate cancer", "kidney cancer", and "bladder cancer") were extracted. We analysed trends for the whole world and for five countries: Italy, the UK, France, Sweden, and the USA. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: A join-point regression model was used to define significant changes in trends over time. Week percentage changes (WPCs) were estimated to summarise linear trends. The Mann-Whitney test was used to compare the search volume during the COVID-19 pandemic period (from January 2020 to April 2021) and the equivalent period of 2018 and 2019. RESULTS AND LIMITATIONS: During COVID-19, worldwide online interest decreased significantly for all urological cancers, especially prostate cancer (WPC: -13.9%,

conclusionsOnline interest in urological cancers decreased significantly during the COVID-19 pandemic. Future studies will tell us whether this will translate into worse oncological outcomes. PATIENT SUMMARY: Patients are increasingly searching the Internet to get information on cancer. We explored Google queries during the COVID-19 pandemic and found that online interest decreased significantly for all urological cancers, especially prostate cancer. We do not know yet whether this will translate into worse prognosis for patients.

Indexed as

CancerCoronavirusGoogle TrendsMass mediaPublic opinionUrology

Identifiers

PMID35072118
PMCPMC8761543
OpenAlexW4206004212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.